[저자] Lindsay B. Kilburn, Dong-Anh Khuong-Quang, Jordan R. Hansford, Daniel Landi, Jasper van der Lugt, Sarah E. S. Leary, Pablo Hernáiz Driever, Simon Bailey, Sébastien Perreault, Geoffrey McCowage, Angela J. Waanders, David S. Ziegler, Olaf Witt, Patricia A. Baxter, Hyoung Jin Kang, Timothy E. Hassall, Jung Woo Han, Darren Hargrave, Andrea T. Franson, Michal Yalon Oren, Helen Toledano, Valérie Larouche, Cassie Kline, Mohamed S. Abdelbaki, Nada Jabado, Nicholas G. Gottardo, Nicolas U. Gerber, Nicholas S. Whipple, Devorah Segal, Susan N. Chi, Liat Oren, Enrica E. K. Tan, Sabine Mueller, Izzy Cornelio, Lisa McLeod, Xin Zhao, Ashley Walter, Daniel Da Costa, Peter Manley, Samuel C. Blackman, Roger J. Packer, Karsten Nysom
[Category] update2024,
[Article Type] Article
[Source] PMC
In a phase 2 trial, the oral type II RAF inhibitor tovorafenib exhibited an overall response rate of 67% in patients with BRAF -altered relapsed/refractory pediatric low-grade glioma.
All Keywords
【저자키워드】 Randomized controlled trials, Drug development, Targeted therapies, Paediatric cancer, Phase II trials,